PE-22-28
PE-22-28 is a synthetic seven-residue peptide derived from spadin, itself a fragment of the propeptide released when the sorting receptor sortilin matures. Spadin was identified as a blocker of the TREK-1 potassium channel. PE-22-28 corresponds to a shortened segment of the spadin sequence and was designed to keep TREK-1 activity in a smaller, more stable molecule.
Product Specifications
- Product: PE-22-28
- Amount: See available options above
- Form: Lyophilized powder
- Purity: Third-party tested by an ISO 17025 U.S. laboratory. See the batch Certificate of Analysis (COA) on this page.
- Storage: Keep sealed and refrigerated at 2–8°C (36–46°F), protected from light.
- Ships from: United States, 2-day UPS
Chemical Profile
- Compound class: Synthetic heptapeptide (spadin analogue)
- Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg (7 residues)
- Molecular formula: C35H55N11O9
- Molecular weight: 773.9 g/mol
- CAS number: 1801959-12-5
What researchers study
TREK-1 (gene KCNK2) is a two-pore-domain potassium channel that helps set the resting membrane potential of neurons. It responds to stretch, temperature, pH and lipids, and it has become a target in neuropharmacology because mice lacking it show altered behavior in standard depression-model tests. PE-22-28 is used to probe this channel:
- Channel electrophysiology: patch-clamp recordings in cells expressing TREK-1, comparing inhibition by spadin and its shortened analogues.
- Peptide stability: how long shortened analogues persist in vivo compared with the parent spadin peptide.
- Behavioral pharmacology: rodent models such as forced-swim and novelty-suppressed feeding tests that are used to study antidepressant-like activity.
- Neuroplasticity markers: hippocampal neurogenesis and synaptic protein expression in mice.
The PE-22-28 literature is small and comes largely from the group that characterized spadin. Findings in rodents and cell systems do not establish effects in humans.
Regulatory status
PE-22-28 is not approved by the FDA for any use. It is sold here as a research reagent only.
Quality & Documentation
Every batch of PE-22-28 is made in small runs for Rogue Compounds and tested by an independent U.S. laboratory for identity (mass spectrometry) and purity (HPLC). Each vial is labeled with its batch number and a QR code that opens the testing lab’s own report for that batch. The same batch Certificate of Analysis is posted on this page and in our COA Library, so you can check one against the other.
Research overview
For a longer look at PE-22-28, covering where it came from, what cell and animal studies have measured, and what the evidence does not show, read our PE-22-28 research overview. It is written as background reading, and every study it cites is linked to PubMed.
Selected literature
- Djillani A, et al. Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity. Front Pharmacol. 2017. PMID 28955242
Research Use Only
This product is sold strictly as a research chemical for in-vitro laboratory and analytical use by qualified professionals. It is not a drug, dietary supplement, food, or cosmetic, and it is not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Rogue Compounds does not provide dosing, preparation, or usage instructions. The literature on this page is listed for scientific background only and does not describe this product or any use of it.
